Advertisement
U.S. markets open in 8 hours 15 minutes

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.5100+0.0800 (+3.29%)
At close: 04:00PM EDT
2.5200 +0.01 (+0.40%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.4300
Open2.4910
Bid2.5400 x 1300
Ask2.7500 x 1400
Day's Range2.4000 - 2.5900
52 Week Range2.0000 - 13.2000
Volume19,459
Avg. Volume172,700
Market Cap3.309M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-29.8500
Earnings DateMar 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYCC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    18 hours agoArgus Research
View more
  • GlobeNewswire

    Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

    BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day. Conference call information: Participant Toll-Free Number: 800-579-2543 Primary Participant Dire

  • GlobeNewswire

    Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

    Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Associatio

  • GlobeNewswire

    Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

    BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The